|
|
|
| Clinical effect of Gliclazide combined with Acarbose in the treatment of type 2 diabetes mellitus |
| TAN Qiu-ling LUO Xiao-jing CHEN Qiao-rong |
| Department of Cardiovascular and Endocrinology,People′s Hospital of Yangdong District in Yangjiang City,Guangdong Province,Yangjiang 529500,China |
|
|
|
|
Abstract Objective To explore the clinical effect of Gliclazide combined with Acarbose in the treatment of type 2 diabetes mellitus(T2DM).Methods A total of 100 cases of T2DM patients admitted to the People′s Hospital of Yangdong District in Yangjiang City from June 2019 to July 2020 were selected as the research objects.According to random number table method,they were divided into the control group and the observation group,with 50 cases in each group.The control group was given Acarbose treatment,while the observation group was given Gliclazide on the basis of the control group.The course of treatment was 12 weeks.The levels of fasting blood glucose(FPG),2 h postprandibular blood glucose(2 h PG),glycosylated hemoglobin(HbA1c),serum hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and the incidence of adverse reactions during treatment were compared between the two groups before and after treatment.Results There were no statistically significant differences in the levels of FPG,2 h PG and HbA1c between the two groups before treatment(P＞0.05).After treatment,the levels of FPG,2 h PG and HbA1c in the two groups were lower than those before treatment,and the levels of FPG,2 h PG and HbA1c in the observation group were lower than those in the control group,the differences were statistically significant(P＜0.05).There were no statistically significant differences in the levels of hs-CRP,IL-6 and TNF-α between the two groups before treatment(P＞0.05).After treatment,the levels of hs-CRP,IL-6 and TNF-α of the two groups were lower than those before treatment,and the levels of hs-CRP,IL-6 and TNF-α of the observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Gliclazide combining with Acarbose in the treatment of T2DM can effectively reducing the levels of FPG,2 h PG,HbA1c,hs-CRP,IL-6 and TNF-α,without increasing the adverse reactions.
|
|
|
|
|
|
| [13] |
朱慧琪.睡前胰岛素联合格列齐特缓释片治疗糖尿病磺脲类药物的疗效研究[J].医药论坛杂志，2015，36（9）：48-49，51.
|
| [14] |
金忆瀛，李玲，厉平.中性粒细胞细胞外陷阱及其抑制剂SerpinB1 与2 型糖尿病的关系[J].中国医师杂志，2020，22（9）：1438-1440，封3.
|
| [15] |
杨晓玉，陈思，杨艳冰，等.渴乐宁胶囊联合格列齐特治疗2型糖尿病的临床研究[J].现代药物与临床，2019，34（2）：489-493.
|
| [16] |
冯雪琴，吴润洁，卢兰芬，等.降钙素原、超敏C 反应蛋白、白细胞介素6、白细胞联合检测在2型糖尿病血流感染诊断中的应用[J].国际检验医学杂志，2018，39（2）：169-172，175.
|
| [1] |
曹雯，范尧夫，孙洪平，等.逆转2 型糖尿病：梦想还是现实[J].国际内分泌代谢杂志，2020，40（5）：315-319.
|
| [2] |
晏群，黄熙涯，孟仲，等.上海市浦东新区糖尿病危险计分筛查2 型糖尿病的效果评价[J].中华糖尿病杂志，2020，12（7）：504-508.
|
| [3] |
纪立农，杜芬，吴晶，等.中国大中城市2 型糖尿病降糖药物治疗患者药物使用调查分析[J].中国药学杂志，2012，47（9）：736-738.
|
| [4] |
马宇航，彭永德.2 型糖尿病降糖药物治疗进展[J].中国临床保健杂志，2020，23（4）：437-445.
|
| [5] |
中华医学会糖尿病学分会.中国2 型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
|
| [6] |
金雯瑜.格列齐特联合利格列汀治疗2型糖尿病的临床研究[J].山西医药杂志，2019，48（17）：2143-2145.
|
| [7] |
彭湾湾，钟雯，曾姣娥，等.利格列汀联合阿卡波糖治疗新发2 型糖尿病患者的疗效与安全[J].成都医学院学报，2020，15（5）：575-577，582.
|
| [8] |
杨知慧，孙立丽，任晓亮.2 型糖尿病危险因素研究进展[J].实用糖尿病杂志，2020，16（6）：83-84.
|
| [9] |
张海风.格列齐特联合阿卡波糖治疗老年2 型糖尿病的效果分析[J].河南医学研究，2017，26（15）：2804.
|
| [10] |
袁兴君.格列齐特联合阿卡波糖治疗2型糖尿病效果观察[J].中国乡村医药，2016，23（12）：25-26.
|
| [11] |
蒋升.2017年ACP《2 型糖尿病口服药物治疗临床实践指南》解读[J].中国全科医学，2017，20（33）：4091-4095，4104.
|
| [12] |
杜施霖，耿文叶，童朝阳.格列齐特缓释片在比格犬体内的药动学及生物等效性[J].第二军医大学学报，2019，40（10）：1162-1166.
|
| [17] |
靳情，严威，孙锐.不同尿白蛋白排泄率2 型糖尿病患者血清chemerin、IL-6 及TNF-α 的表达及意义[J].河北医药，2020，42（2）：192-195.
|
| [18] |
杨琴，王学惠.2 型糖尿病合并冠心病患者血vaspin IL-6水平与其心功能和胰岛素抵抗的相关性[J].安徽医学，2019，40（3）：233-236.
|
| [19] |
于亮宇，杨妮，王静，等.基于TNF-α 和FABP4 蛋白探究长期服用奥氮平导致胰岛素抵抗的作用机制[J].中国医院药学杂志，2020，40（8）：880-884.
|
| [20] |
年雪，王小丽，于东升，等.小檗碱通过抑制Traf2-MEKK1-MEK-ERK 通路改善TNF-α 诱导的胰岛素抵抗[J].现代生物医学进展，2017，17（36）：7001-7007.
|
|
|
|
